Recurrent periorbital low-grade myofibroblastic sarcoma in an infant

Sujeeth Modaboyina, Neelam Pushker, Sahil Agarwal, Sameer Bakhshi1, Seema Sen2, Ruma Ray3, Seema Kashyap2

Key words: Infant tumors, low-grade myofibroblastic sarcoma, periorbital, recurrent tumor, sarcoma

Low-grade myofibroblastic sarcoma (LMFS) is a rare, intermediate grade tumor of myofibroblast cell origin, mostly found in adults. According to a major series, average age of presentation was 40 years (range 9–75 years); 38.7% (24 of 65) occurred in the head and neck region which included lower jaw, sinus, and oral cavity, whereas 41 cases were found in the limbs and other bones, etc.[1]

We hereby report a 10-month-old girl with a reddish lesion, painless progressive, started at the age of 1 month near medial canthus. The baby was born at full-term with uneventful antenatal and postnatal history. No history of similar lesions elsewhere in the body. A 3-month course of oral propranolol was given in the past with a provisional diagnosis of capillary hemangioma with no response. On examination, a solid, firm, non-compressible mass with involvement of skin, reddish in color, with telangiectatic blood vessels was seen, with fixity to underlying bone. It measured 30 mm × 40 mm, located in medial periorbital area [Fig. 1a]. Ocular examination was normal. MRI with contrast showed an intensely enhancing mass with hyperintense T1-weighted and isointense T2-weighted signals [Fig. 1b]. Biopsy was suggestive of LMFS. On light microscopy, fascicles of spindle-shaped tumor cells, with focal storiform pattern, were seen infiltrating soft tissues. Tumor cells had ill-defined eosinophilic cytoplasm and fusiform nuclei. Mild nuclear atypia was seen along with mitotic figs. Ki67-labeling index was >10%. On immunohistochemical...
stains, tumor cells showed cytoplasmic positivity for smooth muscle actin and vimentin [Fig. 1e-h; negative for desmin, myogenin, and S100.

Medical oncologist’s opinion was also sought for neo-adjuvant chemotherapy but LMFSs are mostly resistant to chemotherapy. We planned excision of tumor along with the involved skin. Intra-operatively, tumor was found to be non-encapsulated, solid, and highly vascular. Gross total resection along with the involved skin was performed. Histopathology examination was consistent with LMFS. After 6 months of surgery, patient presented with recurrence at same site [Fig. 1c]. Although the recurrence in skin appeared small, the surrounding area was firm on palpation suggestive of infiltration by the tumor. A repeat MRI was done. Re-surgery was performed, the involved skin was excised, and dissection was carried out in subcutaneous plane with piecemeal removal of tumor done till healthy tissue was visible; superiorly till medial end of eyebrow; medially till contralateral side of nasal bridge; and laterally till medial one third of upper and lower eyelids. Local application of mitomycin-C 0.04% for 5 min soaked in a cotton piece over exposed bone and subcutaneous area was done. A glabellar rotational forehead flap was raised to reconstruct defect. Histopathology showed similar findings. In view of residual tumor, patient was started on tablet pazopanib, 100 mg Once a day (OD), by the medical oncologist. Patient is on the treatment for 7 months with no recurrence [Fig. 1d].

Discussion

LMFS are rare in pediatric age group and even rarer in first decade of life; approximately, 10 cases of LMFS have been reported in the first decade of life but none in infancy (present case at the age of 1 month). Although 2 case reports of LMFS are available in ophthalmic literature, 1 in orbit and another at limbus, respectively, none available in the periorbital region.

We hypothesize that the tissue of origin in our case was cutaneous with subcutaneous infiltrative spread. Because of rarity of LGFS and wide variety of tissue of origin, that is, soft tissues, bone, or organs, imaging characteristics of LGMS is less described. In the present case, though the lesion appeared mostly well-defined, intraoperatively, the tumor was not encapsulated with ill-defined edges. Underlying bone was normal. LGMF sarcomas arising from bone show osteolytic and rarely osteoblastic changes along with the mass lesion.

Primary treatment of LMFS is a wide-surgical excision. Midline of face has important anatomical structures in close proximity, that makes wide-excision of tumor difficult, as was in the present case. Periorbital area, especially near the medial canthus, is considered high risk location for recurrence and hematogenous spread of tumor because of reasons such as, close proximity of tumor to underlying bone, high vascularity, and difficult to perform wide excision due to important anatomical structures in close proximity. Local recurrence reported in LGMF sarcoma is 29.1% (23/79), usually within 6 months to 7 years. Hematogenous spread is reported in 17.7% (14/79); lungs and bones being common sites. Chemotherapy in the form of ifosfamide, vincristine, and etoposide has been attempted in the early cases but with no response. However, recent newer drugs, pirarubicin and nidaiplatin along with ifosfamide, was used as adjunctive treatment after surgical excision in pancreatic LGMS which showed no recurrences till 5 years of follow-up. Radiotherapy
in doses of 45d Gy-66Gy was given for residual tumor which resulted in good response.[7] Pazopanib is an antiangiogenic molecularly targeted drug with effective role in different types of sarcomas.[8]

To the best of our knowledge, this is the first report of occurrence of LMFS that started at the age of 1 month in periorbital region. Further, role of pazopanib to prevent recurrence needs to be emphasized in a recurrent LMFS.

**Declaration of patient consent**
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**References**
1. Wang L, Li LX, Chen DQ, Yang L, Li SK, Cheng C. Low-grade Myofibroblastic sarcoma: Clinical and imaging findings. BMC Med Imaging 2019;19:36.
2. Jayasooriya PR, Athukorala C, Attygalla M, Mendis BRRN, Lombardi T. Low-Grade myofibroblastic sarcoma of the oral cavity: A report of three cases illustrating an emerging disease in children. Dermatopathology (Basel) 2021;8:1-9.
3. Zhang S, Ma Y, Ma T, Wang Z. Low-grade myofibroblastic sarcoma of the orbit: A case report and literature review. Indian J Ophthalmol 2020;68:2538-40.
4. Keller C, Gibbs CN, Kelly SM, Haller JR, White KS, Coffin CM, et al. Low-grade myofibrosarcoma of the head and neck: Importance of surgical therapy. J Pediatr Hematol Oncol 2004;26:119–20.
5. Peng L, Tu Y, Li Y, Xiao W. Low-grade myofibroblastic sarcoma of the pancreas: A case report and literature review. J Can Res Ther 2018;14:796-9.
6. Takácsi-Nagy Z, Muraközy G, Pogány P, Fodor J, Orosz Z. Myofibroblastic sarcoma of the base of tongue. Case report and review of the literature. Strahlenther Onkol 2009;185:198-201.
7. Casali PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol 2012;23:167-9.